

NEW ZEALAND DATA SHEET

1. PRODUCT NAME

ZIAGEN Oral Solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Oral solution containing 20 mg/mL of abacavir as abacavir sulfate.

For the full list of excipients, see section 6.1 List of excipients

3. PHARMACEUTICAL FORM

Oral solution

The oral solution is a clear to slightly opalescent yellowish, aqueous solution which may turn into a brown colour over time with strawberry/banana flavouring.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

ZIAGEN is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.

4.2 Posology and Method of Administration

Adults, adolescents and children weighing at least 25 kg

The recommended dose of ZIAGEN is 300 mg (15 mL) twice daily or 600 mg (30 mL) once daily.

Children \geq three months and weighing less than 25 kg

The recommended dose is 8 mg/kg twice daily or 16 mg/kg once daily up to a maximum dose of 300 mg twice daily or 600 mg once daily.

Children less than three months

The data available on the use of ZIAGEN in this age group are limited (see section 5.2 Pharmacokinetic Properties).

ZIAGEN can be taken with or without food.
ZIAGEN is also available as a tablet formulation.

Therapy should be initiated by a physician experienced in the management of HIV infection.

Renal impairment

No dosage adjustment of ZIAGEN is necessary in patients with renal dysfunction (see section 5.2 Pharmacokinetic Properties).

Hepatic impairment

Abacavir is metabolised primarily by the liver. The recommended dose of ZIAGEN in patients with mild hepatic impairment (Child-Pugh score 5-6) is 200 mg (10 mL) twice a day. Pharmacokinetic and safety data on the use of abacavir in patients with moderate and severe hepatic impairment are not available (see section 5.2 Pharmacokinetic Properties). Therefore the use of abacavir is not recommended in patients with moderate or severe hepatic impairment, unless the benefit of use outweighs the risk.

4.3 Contraindications

ZIAGEN is contraindicated in patients with known hypersensitivity to abacavir or any ingredient of ZIAGEN oral solution.

4.4 Special warnings and precautions for use

Hypersensitivity: (See also section 5.8 Undesirable effects)

Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterised by fever and/or rash with other symptoms indicating multi-organ involvement. HSR can be life-threatening, and in rare cases fatal, when not managed appropriately. The risk for abacavir HSR to occur is significantly increased for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.

The following should be adhered to:

- Testing for HLA-B*5701 status should be considered before initiating abacavir treatment and also before re-starting abacavir treatment in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.
- ZIAGEN is not recommended for use in patients with the HLA-B*5701 allele, or in patients who have had a suspected abacavir HSR while taking any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) regardless of HLA-B*5701 status.
- Each patient should be reminded to read the Patient Leaflet included in the ZIAGEN pack. They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.

- In any patient treated with ZIAGEN, the clinical diagnosis of suspected hypersensitivity reaction must remain the basis of clinical decision making.
- **ZIAGEN must be stopped without delay, even in the absence of the HLA-B*5701 allele, if a HSR is suspected. Delay in stopping treatment with ZIAGEN after the onset of hypersensitivity may result in a life-threatening reaction.**
- Patients who have experienced a hypersensitivity reaction should be instructed to dispose of their remaining ZIAGEN tablets in order to avoid restarting abacavir.
- **Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours, and may include life-threatening hypotension and death.**
- **Regardless of a patient's HLA-B*5701 status, if therapy with any abacavir containing product has been discontinued for any reason and restarting abacavir therapy is under consideration, the reason for discontinuation must be established. If HSR cannot be ruled out, ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) must not be restarted.**
- If a hypersensitivity reaction is ruled out, patients may restart ZIAGEN. Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see section 4.8 Undesirable effects). Patients must be made aware that HSR can occur with reintroduction of ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) and that reintroduction of ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) should be undertaken only if medical care can be readily accessed.

- **Clinical Description of abacavir HSR**

Abacavir HSR has been well characterised through clinical studies and during post marketing follow-up. Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, **although these reactions may occur at any time during therapy.**

Almost all HSR to abacavir include fever and/or rash as part of the syndrome.

Other signs and symptoms that have been observed as part of abacavir HSR include respiratory and gastrointestinal symptoms, **which may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis** (see section 4.8 Undesirable effects). The

symptoms related to HSR worsen with continued therapy and can be life threatening. These symptoms usually resolve upon discontinuation of ZIAGEN.

Lactic Acidosis/Severe Hepatomegaly with Steatosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues either alone or in combination, including abacavir. A majority of these cases have been in women. Clinical features which may be indicative of the development of lactic acidosis include generalised weakness, anorexia, and sudden unexplained weight loss, gastrointestinal symptoms and respiratory symptoms (dyspnoea and tachypnoea). Caution should be exercised when administering ZIAGEN, particularly to those with known risk factors for liver disease. Treatment with ZIAGEN should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis with or without hepatitis (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

Serum lipids and blood glucose

Serum lipid and blood glucose levels may increase during antiretroviral therapy. Disease control and life style changes may also be contributing factors. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.

Immune Reconstitution Syndrome

In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and Pneumocystis jiroveci pneumonia (often referred to as PCP). Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary. Autoimmune disorders (such as Graves' disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.

Opportunistic infections

Patients receiving ZIAGEN or any other antiretroviral therapy may still develop opportunistic infections and other complications of HIV infection. Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.

Myocardial Infarction

Several observational, epidemiological studies have reported an association with abacavir use and the risk of myocardial infarction. Meta-analyses of randomised controlled trials have observed no excess risk of myocardial infarction with abacavir use. To date, there is no established biological mechanism to explain a potential increase in risk. In totality the available data from observational studies and from controlled clinical trials show inconsistency and therefore the evidence for a causal relationship between abacavir treatment and the risk of myocardial infarction is inconclusive.

As a precaution the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimise all modifiable risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking).

Sorbitol

This product contains sorbitol which may cause abdominal pain and diarrhoea. Sorbitol is metabolised to fructose and is therefore unsuitable for patients who have hereditary fructose intolerance.

4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

The potential for medicine interactions involving abacavir is low. *In vitro studies have shown that abacavir has potential to inhibit cytochrome P₄₅₀ 1A1 (CYP1A1).* Abacavir shows limited potential to inhibit metabolism mediated by the CYP3A4 enzyme. It has also been shown *in vitro* not to interact with medicines that are metabolised by CYP2C9 or CYP2D6 enzymes. Induction of hepatic metabolism has not been observed in clinical studies. Therefore, there is little potential for medicine interactions with antiretroviral protease inhibitors and other medicines metabolised by major CYP enzymes. Clinical studies have shown that there are no clinically significant interactions between abacavir, zidovudine, and lamivudine.

Effect of abacavir on the pharmacokinetics of other agents

In vitro, abacavir demonstrates no or weak inhibition of the drug transporters organic anion transporter 1B1 (OATP1B1), OATP1B3, breast cancer resistance protein (BCRP) or P-glycoprotein (Pgp) and minimal inhibition of organic cation transporter 1 (OCT1), OCT2 and multidrug and toxin extrusion protein 2-K (MATE2-K). Abacavir is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.

Abacavir is an inhibitor of MATE1 *in vitro*, however abacavir has low potential to affect the plasma concentrations of MATE1 substrates at therapeutic drug exposures (up to 600 mg).

Effect of other agents on the pharmacokinetics of abacavir

In vitro, abacavir is not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, Multidrug resistance-associated protein 2 (MRP2) or MRP4, therefore drugs that modulate these transporters are not expected to affect abacavir plasma concentrations.

Although abacavir is a substrate of BCRP and Pgp *in vitro*, clinical studies demonstrate no clinically significant changes in abacavir pharmacokinetics when co-administered with lopinavir/ritonavir (Pgp and BCRP inhibitors).

Interactions relevant to abacavir

Ethanol: The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. Given the safety profile of abacavir these findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.

Methadone

In a pharmacokinetic study, coadministration of 600 mg abacavir twice daily with methadone showed a 35% reduction in abacavir C_{max} and a one hour delay in t_{max} , but the AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study abacavir increased the mean methadone systemic clearance by 22%. This change is not considered clinically relevant for the majority of patients, however occasionally methadone re-titration may be required.

Retinoids

Retinoid compounds such as isotretinoin, are eliminated via alcohol dehydrogenase. Interaction with abacavir is possible but has not been studied.

Riociguat

In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine (600 mg/50 mg/300 mg once daily) led to an approximately three-fold higher riociguat $AUC(0-\infty)$ when compared to historical riociguat $AUC(0-\infty)$ reported in healthy subjects. Riociguat dose may need to be reduced, consult the riociguat product labeling for dosing recommendations.

4.6 Fertility, pregnancy and lactation

Pregnancy

Abacavir has been evaluated in the Antiretroviral Pregnancy Registry in over 2000 women during pregnancy and postpartum. Available human data from the Antiretroviral Pregnancy Registry do not show an increased risk of major birth defects for abacavir compared to the background rate (see Clinical efficacy and safety). However, there are no adequate and well-controlled trials in pregnant women and the safe use of ZIAGEN in human pregnancy has not

been established. Abacavir has been associated with findings in animal reproductive studies (see section 5.3 Preclinical safety data).

Therefore administration of ZIAGEN in pregnancy should be considered only if the benefit to the mother outweighs the possible risk to the foetus.

There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed in utero or peri-partum to nucleoside reverse transcriptase inhibitors (NRTIs). The clinical relevance of transient elevations in serum lactate is unknown. There have also been very rare reports of developmental delay, seizures and other neurological disease. However, a causal relationship between these events and NRTI exposure in utero or peri-partum has not been established. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

Breast feeding

Health experts recommend that where possible HIV infected women do not breast feed their infants in order to avoid transmission of HIV. In settings where formula feeding is not feasible, local official lactation and treatment guidelines should be followed when considering breast feeding during antiretroviral therapy.

In a study after repeat oral administration of 300 mg abacavir twice daily (given as Trizivir), the breast milk:maternal plasma ratio was 0.9. Most infants (8 out of 9) had non-detectable levels of abacavir (assay sensitivity 16 ng/mL). Intracellular carbovir triphosphate (active metabolite of abacavir) levels in breastfed infants were not measured therefore the clinical relevance of the serum concentrations of the parent compound measured is unknown.

Fertility

Not applicable

4.7 Effects on ability to drive and use machines

No currently available data suggests that ZIAGEN affects the ability to drive or operate machinery.

4.8 Undesirable effects

For many of the other adverse events reported, it is unclear whether they are related to ZIAGEN, to the wide range of medicinal products used in the management of HIV disease or as a result of the disease process.

Many of those listed below (nausea, vomiting, Diarrhea, fever, fatigue, rash) occur commonly as part of abacavir hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. If ZIAGEN has been discontinued in patients due to experiencing any one of these symptoms and a decision is made to restart

ZIAGEN, this should be done only under direct medical supervision (see Special considerations following an interruption of ZIAGEN therapy).

The majority of the adverse reactions listed below have not been treatment limiting. The following convention has been used for their classification:- very common (>1/10), common (>1/100, <1/10), uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000), very rare (<1/10,000).

Metabolism and nutrition disorders

Common: anorexia, hyperlactataemia

Rare: lactic acidosis (see section 4.4 Special warnings and precautions for use).

Nervous system disorders

Common: headache

Gastrointestinal disorders:

Common: nausea, vomiting, diarrhoea

Rare: pancreatitis has been reported, but a causal relationship to ZIAGEN treatment is uncertain.

Skin and subcutaneous tissue disorders

Common: rash (without systemic symptoms)

Very rare: erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis

General disorders and administration site disorders:

Common: fever, lethargy, fatigue

In controlled clinical studies laboratory abnormalities related to ZIAGEN treatment were uncommon, with no differences in incidence observed between ZIAGEN treated patients and the control arms.

Paediatric population:

The safety database to support abacavir once daily dosing in paediatric patients comes from the ARROW Trial (COL105677) in which 669 HIV-1 infected paediatric subjects received abacavir and lamivudine either once or twice daily (see Clinical efficacy and safety). No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.

Description of Selected Adverse Reactions

Hypersensitivity (see also section 4.4 Special warnings and precautions for use):

Abacavir hypersensitivity reaction (HSR) has been identified as a common adverse reaction with abacavir therapy. The signs and symptoms of this hypersensitivity reaction are listed below. These have been identified either from clinical studies or post marketing surveillance. Those reported in at **least 10% of patients** with a hypersensitivity reaction are in bold text.

Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however, reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.

Skin:	Rash (usually maculopapular or urticarial)
Gastrointestinal tract:	Nausea, vomiting, diarrhoea, abdominal pain, mouth ulceration
Respiratory tract:	Dyspnoea, cough, sore throat, adult respiratory distress syndrome, respiratory failure
Miscellaneous:	Fever, fatigue, malaise, oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis
Neurological/Psychiatry:	Headache, paraesthesia
Haematological:	Lymphopenia
Liver/pancreas:	Elevated liver function tests, hepatic failure
Musculoskeletal:	Myalgia, rarely myolysis, arthralgia, elevated creatine phosphokinase
Urology:	Elevated creatinine, renal failure

Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours. This recurrence of the HSR is usually more severe than on initial presentation, and may include life-threatening hypotension and death. Reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).

For details of clinical management in the event of a suspected abacavir HSR see section 4.4 Special warnings and precautions for use.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via: <https://nzphvc.otago.ac.nz/reporting>

4.9 Overdose

Single doses up to 1200 mg and daily doses up to 1800 mg of abacavir have been administered to patients in clinical studies. No unexpected adverse reactions were reported. The effects of higher doses are not known. If overdose occurs the patient should be monitored for evidence of toxicity (see section 4.8 Undesirable effects), and standard supportive treatment applied as necessary. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5.0 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: nucleoside analogue, ATC Code: J05AF06

Mechanism of action

Abacavir is a nucleoside analogue reverse transcriptase inhibitor. It is a potent selective inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced susceptibility to zidovudine, lamivudine, zalcitabine, didanosine or nevirapine. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). *In vitro* studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. The antiviral activity of abacavir in cell culture was not antagonised when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.

Pharmacodynamic effects

Abacavir-resistant isolates of HIV-1 have been selected *in vitro* and are associated with specific genotypic changes in the reverse transcriptase (RT) codon region (codons M184V, K65R, L74V and Y115F). Viral resistance to abacavir develops relatively slowly *in vitro* and *in vivo*, requiring multiple mutations to reach an eight fold increase in IC₅₀ over wild-type virus, which may be a clinically relevant level.

Isolates resistant to abacavir may also show reduced sensitivity to lamivudine, zalcitabine and/or didanosine, but remain sensitive to zidovudine and stavudine. Cross resistance between abacavir and protease inhibitors or non nucleoside reverse transcriptase inhibitors is unlikely. Treatment failure following initial therapy with abacavir, lamivudine and zidovudine is mainly associated with the M184V alone, thus maintaining many therapeutic options for a second line regimen.

Clinical efficacy and safety

In clinical studies, treatment with ZIAGEN in combination with zidovudine and lamivudine was associated with significant and sustained reductions in viral load, with corresponding rises in CD₄ cell count in adults and children.

In a double-blind clinical study over 48 weeks in treatment naïve adult patients, the combination of abacavir, lamivudine and zidovudine showed an equivalent antiviral effect to the combination with indinavir, lamivudine and zidovudine in the primary analysis of efficacy. In a secondary analysis of patients with baseline plasma HIV-1 RNA levels above 100,000 copies per mL, patients receiving the combination containing indinavir had a superior response. Patients with baseline plasma HIV-1 RNA below 100,000 copies per mL had an equivalent response to both treatments.

A randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). After 36 weeks on a regimen including twice daily abacavir and lamivudine, 669 eligible subjects were randomised to either continue twice daily dosing or switch to once daily abacavir and lamivudine for at least 96 weeks. The results are summarised in the table below:

Virological Response Based on Plasma HIV-1 RNA less than 80 copies/mL at Week 48 and Week 96 in the Once Daily versus Twice Daily abacavir + lamivudine randomisation of ARROW (Observed Analysis)

	Twice Daily n/N (%)	Once Daily n/N (%)
Week 0 (After ≥36 Weeks on Treatment)		
Plasma HIV-1 RNA <80 c/mL	250/331 (76)	237/335 (71)
Risk difference (once daily-twice daily)	-4.8% (95% CI -11.5% to +1.9%), p=0.16	
Week 48		
Plasma HIV-1 RNA <80 c/mL	242/331 (73)	236/330 (72)
Risk difference (once daily-twice daily)	-1.6% (95% CI -8.4% to +5.2%), p=0.65	
Week 96		

Plasma HIV-1 RNA <80 c/mL	234/326 (72)	230/331 (69)
Risk difference (once daily-twice daily)	-2.3% (95% CI -9.3% to +4.7%), p=0.52	

The abacavir/lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of <80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (<200 c/mL, <400 c/mL, <1000 c/mL), which all fell well within this non-inferiority margin. Subgroup analyses testing for heterogeneity of once vs twice daily demonstrated no significant effect of sex, age, or viral load at randomisation. Conclusions supported non-inferiority regardless of analysis method.

In a study comparing the unblinded NRTI combinations (with or without blinded nelfinavir) in children, a significantly greater proportion treated with abacavir and lamivudine (73%) or abacavir and zidovudine (70%) had HIV-1 RNA \leq 400 copies/mL at 24 weeks, compared with those treated with lamivudine and zidovudine (44%). In children with extensive antiretroviral exposure, a modest but sustained effect of the combination of abacavir, lamivudine and zidovudine was observed.

In therapy experienced patients, limited data show that the addition of ZIAGEN to nucleoside reverse transcriptase inhibitors provides additional benefit in reducing viral load, and increasing CD₄ cell count. The degree of benefit will depend on the nature and duration of prior therapy which may have selected for cross resistance to abacavir.

Abacavir penetrates the cerebrospinal fluid (CSF) (see section 5.2 Pharmacokinetic properties), and has been shown to reduce HIV-1 RNA levels in the CSF. In combination with other antiretrovirals it may have a role in the prevention of HIV related neurological complications, and may delay the development of resistance in this sanctuary site.

Antiretroviral Pregnancy Registry

The Antiretroviral Pregnancy Registry has received prospective reports of over 2,000 exposures to abacavir during pregnancy resulting in live birth. These consist of over 800 exposures during the first trimester, over 1,100 exposures during the second/third trimester and included 27 and 32 birth defects respectively. The prevalence (95% CI) of defects in the first trimester was 3.1% (2.0, 4.4%) and in the second/third trimester, 2.7% (1.9, 3.9%). Among pregnant women in the reference population, the background rate of birth defects is 2.7%. There was no association between abacavir and overall birth defects observed in the Antiretroviral Pregnancy Registry.

5.2 Pharmacokinetic Properties

Absorption

Abacavir is rapidly and well absorbed following oral administration. The absolute bioavailability of oral abacavir in adults is about 83%. Following oral administration, the mean time (t_{max}) to maximal serum concentrations of abacavir is about 1.5 hours for the tablet formulation and about 1.0 hour for the solution formulation.

There are no differences observed between the AUC for the tablet or solution. At therapeutic dosages (300 mg twice daily), the steady state C_{max} of abacavir tablets is approximately 3 micrograms/mL, and the AUC over a dosing interval of 12 hours is approximately 6 micrograms.h/mL. The C_{max} value for the oral solution is slightly higher than the tablet.

Food delayed absorption and decreased C_{max} but did not affect overall plasma concentrations (AUC). Therefore ZIAGEN can be taken with or without food.

Distribution

Following intravenous administration, the apparent volume of distribution was about 0.8 L/kg, indicating that abacavir penetrates freely into body tissues.

Studies in HIV infected patients have shown good penetration of abacavir into the cerebrospinal fluid (CSF), with a CSF to plasma AUC ratio of between 30 to 44%. In a Phase I pharmacokinetic study, the penetration of abacavir into the CSF was investigated following administration of abacavir 300 mg twice a day. The mean concentration of abacavir achieved in the CSF 1.5 hours post dose was 0.14 micrograms/mL. In a further pharmacokinetic study of 600 mg twice a day, the CSF concentration of abacavir increased over time, from approximately 0.13 micrograms/mL at 0.5 to 1 hour after dosing, to approximately 0.74 micrograms/mL after 3 to 4 hours. While peak concentrations may not have been attained by 4 hours, the observed values are 9 fold greater than the IC₅₀ of abacavir of 0.08 micrograms/mL or 0.26 micromolar.

Plasma protein binding studies *in vitro* indicate that abacavir binds only low to moderately (circa 49%) to human plasma proteins at therapeutic concentrations. This indicates a low likelihood for medicine interactions through plasma protein binding displacement.

Metabolism

Abacavir is primarily metabolised by the liver with less than 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5'-carboxylic acid and 5'-glucuronide which account for about 66% of the administered dose. These metabolites are excreted in the urine.

Elimination

The mean half-life of abacavir is about 1.5 hours. Following multiple oral doses of abacavir 300 mg twice a day there is no significant medicine accumulation. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83% of the administered abacavir dose in the urine the remainder is eliminated in the faeces.

Special populations

Hepatically impaired

Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5-6). The results showed that there was a mean increase of 1.89 fold in the abacavir AUC, and 1.58 fold in the half-life of abacavir. The AUCs of the metabolites were not modified by the liver disease. However, the rates of formation and elimination of these were decreased.

In order to achieve exposures that are within the therapeutic range of patients without liver disease, patients with mild hepatic impairment should receive 200mg abacavir twice daily. The pharmacokinetics have not been studied in patients with moderate or severe hepatic impairment, therefore ZIAGEN is not recommended in these patient groups.

Renally impaired

Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function. Therefore no dosage reduction is required in patients with renal impairment.

Children

Abacavir is rapidly and well absorbed from oral solution and tablet formulations administered to children. Plasma abacavir exposure has been shown to be the same for both formulations when administered at the same dose. Children receiving abacavir oral solution according to the recommended dosage regimen achieve plasma abacavir exposure similar to adults. Children receiving abacavir oral tablets according to the recommended dosage regimen achieve higher plasma abacavir exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation (see section 4.2 Posology and Method of Administration). Paediatric pharmacokinetic studies have demonstrated that once daily dosing provides equivalent AUC₀₋₂₄ to twice daily dosing of the same total daily dose for both oral solution and tablet formulations. There are insufficient safety data to recommend the use of ZIAGEN in infants less than three months old. The limited data available indicate that a dose of 2 mg/kg in neonates less than 30

days old provides similar or greater AUCs, compared to the 8 mg/kg dose administered to older children.

Elderly

The pharmacokinetics of abacavir have not been studied in patients over 65 years of age. When treating elderly patients consideration needs to be given to the greater frequency of decreased hepatic, renal and cardiac function, and concomitant disease or other medicine therapy.

5.3 Preclinical safety data

Mutagenicity and carcinogenicity

Abacavir was not mutagenic in bacterial tests but showed activity *in vitro* in the human lymphocyte chromosome aberration assay, the mouse lymphoma assay, and the *in vivo* micronucleus test. This is consistent with the known activity of other nucleoside analogues. These results indicate that abacavir is a weak clastogen both *in vitro* and *in vivo* at high test concentrations.

Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver, urinary bladder, lymph nodes and the subcutis of female rats.

The majority of these tumours occurred at the highest abacavir dose of 330 mg/kg/day in mice and 600 mg/kg/day in rats. These dose levels were equivalent to 24 to 32 times the expected systemic exposure in humans. The exception was the preputial gland tumour which occurred at a dose of 110 mg/kg. This is equivalent to six times the expected human systemic exposure. There is no structural counterpart for this gland in humans. While the carcinogenic potential in humans is unknown, these data suggest that a carcinogenic risk to humans is outweighed by the potential clinical benefit.

Repeat-dose toxicity: Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined.

Reproductive toxicology

Placental transfer of abacavir and/or its related metabolites has been shown to occur in animals. Evidence of toxicity to the developing embryo and foetuses occurred only in rats at maternally toxic doses of 500 mg/kg/day and above. This dose is equivalent to 32 to 35 times human therapeutic exposure based on AUC. The findings included foetal oedema, variations and malformations, resorptions, decreased foetal body weight and an increase in still births. The dose at which there were no effects on pre or post natal

development was 160 mg/kg/day. This dose is equivalent to an exposure of about 10 times that in humans. Similar findings were not observed in rabbits.

A fertility study in the rat has shown that doses up to 500 mg/kg of abacavir had no effect on male or female fertility.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Sorbitol (34%).
Saccharin sodium.
Sodium citrate dihydrate.
Citric acid.
Methyl hydroxybenzoate.
Propyl hydroxybenzoate.
Propylene glycol.
Artificial strawberry and banana flavour.
Purified water.

6.2 Incompatibilities

None known.

6.3 Shelf Life

2 years.

Discard oral solution two months after first opening.

6.4 Special Precautions for Storage

Store below 30°C.

6.5 Nature and Contents of Container

ZIAGEN Oral Solution is supplied in high density polyethylene bottles with child-resistant closures, containing 240 mL of oral solution. A 10 mL oral dosing syringe and an adapter are also included in the pack.

An oral dosing syringe is provided for accurate measurement of the prescribed dose of oral solution. Instructions for use are included in the pack.

6.6 Special precautions for disposal

No special requirements for disposal

7. MEDICINE SCHEDULE

Prescription Medicine

8. Sponsor

GlaxoSmithKline NZ Limited
Private Bag 106600
Downtown Auckland
New Zealand

Phone: (09) 367 2900
Facsimile: (09) 367 2910

9. DATE OF FIRST APPROVAL

Date of publication in the New Zealand Gazette of consent to distribute the medicine: 24 March 2001

10. DATE OF REVISION OF THE TEXT

12 January 2023

Summary table of changes

Section changed	Summary of new information
4.4	Removal of warning regarding transmission of infection due to data regarding Undetectable = Untransmittable
4.2; 4.5; 5.1	Editorial updates

Version: 15.0

Trade marks are owned by or licensed to the ViiV Healthcare Group of Companies.

© 2023 GSK group of companies or its licensor.